Drug Discovery Services Industry Growth, Development and Demand Forecast to 2030

The global drug discovery services market, valued at USD 21.0 billion in 2023, is projected to reach USD 54.2 billion by 2030, reflecting a Compound Annual Growth Rate (CAGR) of 14.7% from 2024 to 2030.

Driving Factors of Market Growth

The market's expansion is fueled by several key factors:

• Increased R&D investments from the biopharmaceutical and pharmaceutical sectors.
• Rising demand for outsourced analytical testing facilities.
• Initiatives focused on orphan drug and rare disease research.
• High costs associated with in-house drug development processes.

The escalating costs of R&D activities, especially those targeting orphan drugs for rare conditions, drive the demand for outsourced clinical testing and analytical research services.

Biopharmaceutical Industry Trends

The biopharmaceutical sector is experiencing significant growth due to:

• Rising demand for biologics.
• Development and production of innovative, life-saving drugs.
• Continued investment in research for new drugs targeting both common and rare diseases.
• Addressing challenges related to patent expirations and the growing need for biologics in emerging markets.

Download free sample copy of this report: https://www.psmarketresearch.com/market-analysis/drug-discovery-services-market-report/report-sample

Key Insights

• In 2023, the hit-to-lead identification segment captured the largest market share of 35% in the drug discovery services sector. This process is essential in early-stage drug research and is often outsourced to achieve economies of scale and efficiency. Advances in in-silico methods, including computer-aided drug discovery and structure-based drug design, are driving this segment. High-throughput screening (HTS) is also critical in hit-to-lead identification, supported by advancements in robotics, liquid handling, plate reader technologies, and computing power. Due to the specialized and costly nature of HTS, many organizations, particularly those with limited funding, opt to outsource these services to Contract Research Organizations (CROs) for high-quality, cost-effective solutions.

• The chemistry segment held a dominant market share of 60% in 2023. Medicinal chemistry plays a vital role throughout the drug development process, from pre-clinical evaluation to the delivery of a drug candidate. The market for medicinal chemistry is expanding as companies increasingly outsource R&D tasks to manage overhead costs associated with pharmaceutical discovery and development. Small-molecule drugs, representing 50% of specialty drug sales and over 75% of all FDA approvals in 2020, are crucial in developing new treatments for cancer, autoimmune diseases, cardiovascular disorders, and respiratory conditions.

Regional Insights

• North America holds the largest market share of 55% in the drug discovery services industry. The region benefits from numerous CROs and Contract Manufacturing Organizations (CMOs) supporting major pharmaceutical and biopharmaceutical companies, driving industry growth. Many newly developed drugs have their patents registered in the U.S., further boosting the market. Key factors contributing to industry growth include an aging population, increasing prevalence of chronic diseases, technological advancements in biotechnology and pharmaceuticals, established reimbursement policies, advanced healthcare infrastructure, greater awareness of early disease diagnosis, and initiatives to improve patient care.

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.